Fact sheets
These information sheets explain what the clinical care standard means for consumer, clinicians and healthcare services.
What do clinicians need to know?
The standard contains eight quality statements to ensure the safe and appropriate use of psychotropic medicines in people with cognitive disability or impairment.
The Psychotropic Medicines in Cognitive Disability or Impairment Clinical Care Standard includes links to resources that may help healthcare services and clinicians to implement the standard. These resources are listed under the relevant quality statements below.
Clinicians, consumers and healthcare services have been consulted during the development of the Standard.
Endorsing organisations
The Psychotropic Medicines in Cognitive Disability or Impairment Clinical Care Standard has been endorsed by the following organisations:
Quality statements
The quality statements describe the expected standard for key components of patient care. By describing what each statement means, they support:
2024
Newsletter
This issue includes items on maternal morbidity, the Patient-Reported Indicator Surveys, opioid stewardship, airway management, patient experiences and patient belongings, low back pain, COVID-19, and more.
Also covered are the latest issues of The Joint Commission on Quality and Patient Safety and Australian Health Review along with early online papers from BMJ Quality & Safety and the latest from the UK’s NICE and NIHR and the USA’s AHRQ.
On the Radar Issue 635 is now available.
2023
Publication, report or update
This Requirement sets out the standards for using Human Papillomavirus nucleic acid testing as the primary screening method for cervical cancer screening.
This document will be replacing three previous Tier 4 NPAAC documents, namely:
On the Radar Issue 634 is now available.